PALB2 and pachyonychia congenita: Alternatively somatic tumor test follows these recommendations: tumor testing for somatic HR gene mutations (i.e., BRCA1/2, ATM, PALB2, RAD51D, FANCA, and CHEK2) and MSI/dMMR can be considered in patients with regional or mPC; multigene molecular testing can be considered for patients with low- and favorable-intermediate risk PC and life expectancy ≥10 years; the Decipher molecular assay can be considered as part of counseling for risk stratification in patients with prostatic specific antigen (PSA) resistance/recurrence after radical prostatectomy.